FindTrial
Sign In

A 6-month single-center, randomized, controlled, blind end-point trial to explore the possible application value of cognitive training in improving patients with mild cognitive impairment and early Alzheimer's disease

A 6-month single-center, randomized, controlled, blind end-point trial to explore the possible application value of cognitive training in improving patients with mild cognitive impairment and early Alzheimer's disease

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072479
Enrollment
Unknown
Registered
2023-06-14
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Interventions

Intervention group:Received 40 minutes of daily intervention training for six months from a cognitive training mini-program developed by Best Covered
Control group:Daily health education for six months

Sponsors

Beijing Tiantan Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Age 50-85 years old; (2) Patients with AD who meet the 2011 National Institute on Aging and Alzheimer's Association (NIA-AA) diagnostic criteria for "AD-derived MCI" or "probable AD dementia" or meet the 2018 NIA-AA diagnostic framework for "ATN"; (3) Able to understand the instructions and cooperate with the improvement of serological tests, scale evaluation and brain magnetic resonance examination; (4) There is a researcher partner who can participate in the whole process.

Exclusion criteria

Exclusion criteria: (1) There are other central system diseases that may cause cognitive impairment, such as stroke, frontotemporal dementia, Parkinson's disease, epilepsy, tumor, encephalitis, etc.; (2) A history of mental illness consistent with the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis; (3) Cognitive impairment after traumatic brain injury; (4) there is a history of drug abuse or alcohol dependence, a history of poisoning or a history of exposure to harmful substances such as radiation; (5) unstable or serious heart, lung, liver, kidney, hematopoietic system diseases, poor physical condition, or the existence of major diseases, life expectancy is very short; (6) Claustrophobia, or 3.0T magnetic resonance imaging contraindo, such as metal implants, pacemakers, dental implants, etc., and poor image quality, unable to complete subsequent data processing. (7) Participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Alzheimer disease assessment scale-cog;activities of daily living;Neuropsychiatric Inventory;—

Countries

China

Contacts

Public ContactJun Xu

Beijing Tiantan Hospital Affiliated to Capital Medical University

neurojun@126.com+86 135 8156 9328

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026